Skip to content
Peptide research

Syn-Coll

Also known as Palmitoyl Tripeptide-5
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A synthetic peptide applied to skin, marketed for firmness and fine-line reduction by signaling skin cells into collagen-production mode. Human evidence is thin, limited to small trials of modest wrinkle improvement, while deeper collagen claims rest mainly on lab reasoning. Safety data is limited, reported issues mild (dryness, occasional sensitivity). Not an approved drug in the US; it is sold as a cosmetic ingredient, subject to applicable cosmetic safety and labeling requirements.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Stimulation of type I and type III collagen synthesis via TGF-beta activation

    Speculative

    No independent study confirms TGF-beta activation; evidence is supplier in-vitro data only.

  • Reduction of facial wrinkles (depth, area, and roughness)

    Low

    Two small open-label human studies report wrinkle reduction, but neither isolates this peptide alone.

  • Improved skin firmness, elasticity, and pore appearance

    Speculative

    Firmness and density gains reported in combination-product studies; pore effects were not studied.

Evidence limits

Evidence Level
Moderate

Clinical evidence for Syn-Coll is moderate and primarily manufacturer-sponsored. The strongest clinical data comes from DSM/Firmenich's 84-day study with 60 volunteers demonstrating dose-dependent wrinkle reduction (7-12%) measured by PRIMOS surface topography, with Syn-Coll outperforming both placebo (3.5x) and palmitoyl pentapeptide-3. A separate 33-person study showed subjective improvements in firmness (77%) and pore appearance (60%) at 4 weeks. In vitro evidence for TGF-beta activation and 2-3 fold collagen increases is consistent and well-characterized. A 2020 nanoliposome delivery study with 15 women provided additional human evidence showing wrinkle volume reduction (25%) and elasticity improvement (36.6%) when Syn-Coll was combined with carnosine and Argireline. However, as noted by Resende et al. 2021 (PMID 34451799), neither efficacy studies for the use of palmitoyl tripeptide-5 alone nor in sensitive skin applications meeting rigorous independent clinical trial standards are available. The cited CIR review does not establish a final safety conclusion for palmitoyl tripeptide-5.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Mild skin dryness or flaking

    Low
  • Allergic or sensitivity reaction (rare)

    Low
  • Theoretical TGF-beta pathway concerns

    Theoretical
  • Limited long-term safety data

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.